“异病同治”是中药复方临床应用特色之一，如何选择与“异病同治”药效关联的质控指标是中药复方质量评价领域的关键科学问题。本项目拟以“心脑同治”的银丹心脑通软胶囊为载体，建立“向前逐步选择法-多维药效指标共评价”的药效成分组合筛选方法，探索具有“异病同治”作用的中药复方质量控制新模式。具体如下：（1）解析银丹心脑通软胶囊化学成分及体内代谢过程；（2）以高内涵细胞成像评价各成分及组合在心、脑保护作用中的多重、动态药效，基于“向前逐步选择法”和多维药效指标共评价模型筛选“心脑同治”成分组合，并以小鼠模型进行药效验证；（3）从整体代谢网络调控和线粒体损伤保护两方面，探讨“心脑同治”作用机制；（4）基于“心脑同治”药效成分组合的量效关系，建立与临床疗效相关联、以“心脑同治”成分组合为标示的质量控制新方法。本项目以“心脑同治”中药开展示范性研究，为探索具有多效性中药的质量控制模式提供新的思路与方法支撑。

In Chinese medicine, “the same treatment for different disease” is a characteristic application of traditional Chinese medicine (TCM) in the clinic. How to select the markers represented the multi-bioactivities is still the key problem in quality control of TCMs. Yindan Xinnaotong Capsule (YXC) is widely used to treat cardiovascular and cerebrovascular disease, the efficacy is called as “heart-brain concurrent regulation”. In this project, taking YXC as an example, we will develop a new strategy based on “forward selection stepwise regression- multi-dimensional pharmacodynamics evolution” to select the combinatorial markers for TCM quality control. This project includes four components: (1) The comprehensive chemical profiling and metabolic disposition research; (2) The High-Content Screening technique will be applied to acquire the multi- and dynamics parametric data (representative the heart and brain protection) of the components from YXC, the forward selection stepwise regression and multi-dimensional pharmacodynamic evaluation will be established, and applied for the combinatorial markers of heart-brain concurrent regulation (HBCRCCs) screening; then the efficacy of HBCRCCs will be confirmed in vivo; (3) Expounding the interaction modes and mechanism according to the endogenous network regulation and injured mitochondria protection; (4) A new quality control method of YXC will be developed based on the quantity-effect relationship of HBCRCCs. The research strategy proposed here will provide a new thought and methodological support for the quality control mode of TCM with multi- integrative effects.